rotenone has been researched along with Parkinsonian Disorders in 201 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (17.91) | 29.6817 |
| 2010's | 122 (60.70) | 24.3611 |
| 2020's | 43 (21.39) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Z; Chen, J; Fu, C; Li, M; Liu, L; Peng, Y; Xie, A; Zhang, H; Zhou, X | 1 |
| Chen, CN; Chen, SM; Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH | 1 |
| Akindahunsi, AA; Akinmoladun, AC; Famusiwa, CD; Josiah, SS; Lawal, AO; Olaleye, MT | 1 |
| Akindahunsi, AA; Akinmoladun, AC; Crown, OO; Famusiwa, CD; Josiah, SS; Lawal, AO; Olaleye, MT | 1 |
| Gurke, R; Manderscheid, C; Niederberger, E; Schreiber, Y; Tegeder, I; Wilken-Schmitz, A | 1 |
| Mousa, HH; Nader, MA; Sharawy, MH | 1 |
| Atta, R; El-Baz, AA; Imbaby, S; Khalil, S; Mahmoud, OM; Mohammad, HMF | 1 |
| Allodi, S; Correa, CL; de Andrade Gomes, CAB; de Barros, CM; Medeiros, TB; Mello, AA; Nogueira, NDS | 1 |
| Buneeva, OA; Kapitsa, IG; Kazieva, LS; Kopylov, AT; Medvedev, AE; Vavilov, NE; Zgoda, VG | 1 |
| El-Deeb, AM; El-Tanbouly, DM; El-Yamany, MF; Mohamed, AF | 1 |
| Albalawi, MA; Alzlaiq, WA; Atif, HM; Bilasy, SE; Eladl, MA; Elaidy, SM; ElSayed, MH; Farag, NE; Helal, MA; Helaly, AMN; Hisham, FA; Ibrahiem, AT; Khella, HWZ; Osman, NMS; Zaitone, SA | 1 |
| Anguchamy, V; Muthuvel, A | 1 |
| Buneeva, OA; Kapitsa, IG; Kazieva, LS; Vavilov, NE; Zgoda, VG | 1 |
| Afzal, A; Ahmad, S; Batool, Z; Haider, S; Liaquat, L; Madiha, S; Mehdi, BJ; Sadir, S; Sajid, I; Shahzad, S; Tabassum, S | 1 |
| El-Khatib, AS; Khattab, MM; Mansour, HM; Mohamed, AF | 1 |
| Buneeva, OA; Kapitsa, IG; Medvedev, AE; Zgoda, VG | 1 |
| Ding, Y; Huang, W; Kong, D; Li, L; Lim, K; Lu, X; Ma, B; Wang, Q; Wu, Q; Xin, C; Xu, J; Yang, ND; Zhang, C; Zhang, H; Zhou, T | 1 |
| Bandookwala, M; Khairnar, A; Sahu, AK; Sengupta, P; Sharma, M; Thakkar, D | 1 |
| Altinoz, MA; Alturfan, AA; Ateş, PS; Çalışkan-Ak, E; Elmaci, I; Emekli-Alturfan, E; Ünal, İ; Üstündağ, ÜV | 1 |
| Akindahunsi, AA; Akinmoladun, AC; Ilesanmi, OB; Josiah, SS; Olaleye, MT | 1 |
| Chang, KC; Fang, CH; Li, KY; Lin, YW; Soung, HS; Tsai, CC; Tseng, HC; Wang, MH; Yang, CC | 1 |
| Agrawal, N; Garabadu, D | 1 |
| Bagle, S; Dighe, V; Kaikini, A; Muke, S; Peshattiwar, V; Sathaye, S | 1 |
| Margabandhu, G; Vanisree, AJ | 1 |
| Dai, Y; Hou, S; Jiang, N; Lin, Q; Lin, Y | 1 |
| Gu, R; Li, T; Liu, XJ; Ren, YP; Tian, JY; Tu, L; Wang, BJ; Wang, Q; Yang, XL; Zhang, GP | 1 |
| Abdel-Hafez, SMN; Abdelwahab, S; Elsebay, SAG; Fouli Gaber, M | 1 |
| Adeniyi, PA; Agedah, AE; Awogbindin, IO; Farombi, EO; Ogbuewu, E; Olorunkalu, PD; Oyetunde, BF | 1 |
| Birla, H; Dilnashin, H; Keswani, C; Rai, SN; Rathore, AS; Singh, R; Singh, RK; Singh, SP; Singh, SS; Zahra, W | 1 |
| Freeman, JL; Wasel, O | 1 |
| Bilge, SS; Cankara, FN; Günaydın, C; Kortholt, A; Özmen, Ö | 1 |
| Munissi, JJE; Nyandoro, SS; Siima, AA; Stephano, F | 1 |
| Chen, L; Chen, P; Song, N; Wang, Y; Xie, J | 1 |
| Hong, JS; Hou, L; Jing, L; Li, S; Peng, B; Ruan, Z; Wang, Q; Zhang, D; Zhang, X; Zhao, J | 1 |
| Ge, XQ; He, Y; Hong, YX; Huang, WM; Qiu, L; Sun, Y; Tang, PC; Yu, BC; Zhang, X; Zhang, XL; Zhang, XY | 1 |
| Kumar, P; Kumar, S | 1 |
| Ammar, RM; El-Bahy, AAZ; El-Naga, RN; Labib, AY; Michel, HE; Tadros, MG | 1 |
| Belosludtseva, NV; Karaban, IN; Mankovskaya, IN; Mikheeva, IB; Mironova, GD; Mosentsov, AA; Putiy, YV; Rozova, EV | 1 |
| Chen, Y; Du, L; Ge, M; Kang, X; Li, C; Li, Y; Liu, Y; Wang, W; Wang, Y; Zhang, W; Zhang, X | 1 |
| Alves, BDS; Araújo, GMS; Barros, PAB; Dora, CL; Fernandes, SS; Ferreira, SP; Hort, MA; Monteiro, LKS; Ramires Júnior, OV; Rodrigues, JL; Vaz, GR | 1 |
| Buck, SA; De Miranda, BR; Fish, KN; Freyberg, Z; Greenamyre, JT; Logan, RW | 1 |
| Ahmed, YR; Aziz, WM; Hamed, MAA; Khalil, WKB; Naser, AFA | 1 |
| Arab, A; Chovsepian, A; Drazanova, E; Hadjistyllis, C; Khairnar, A; Pan-Montojo, F; Rektorova, I; Ruda-Kucerova, J; Sejnoha Minsterova, A; Shang, Q; Starcuk, Z; Szabó, N | 1 |
| Guo, Q; Liu, Z; Smith, WW; Wang, B; Wang, X; Zhu, Y | 1 |
| Cacabelos, R; Egea, J; Farré-Alins, V; González-Lafuente, L; Parada, E; Ramos, E; Romero, A | 1 |
| Ebrahimi, SS; Hassanzadeh, K; Izadpanah, E; Oryan, S | 1 |
| Jagota, A; Mattam, U | 1 |
| Aksoy, D; Ateş, U; Çavuşoğlu, T; Erbaş, O; Meral, A; Solmaz, V | 1 |
| Kim, C; Ko, YU; Lee, J; Oh, YJ | 1 |
| Shen, D; Song, R; Tian, X; Zhang, B | 1 |
| Chen, J; Cheng, XY; Deng, WB; Li, SY; Li, XK; Liu, CF; Mao, CJ; Wang, F; Wang, GH; Wang, MX | 1 |
| Bal-Price, A; Bennekou, SH; Leist, M; Monnet-Tschudi, F; Paini, A; Schildknecht, S; Terron, A | 1 |
| Neerati, P; Palle, S | 1 |
| Bai, Q; Burton, EA; De Miranda, BR; El Ayadi, A; Hinkle, D; Rocha, EM; Timothy Greenamyre, J | 1 |
| Costa, AJ; Erustes, AG; Pereira, GJDS; Sinigaglia-Coimbra, R; Smaili, SS; Ureshino, RP | 1 |
| Mbiydzenyuy, NE; Ninsiima, HI; Pieme, CA; Valladares, MB | 1 |
| Balakrishnan, R; Dhanraj, V; Elangovan, N; Karuppaiah, J | 1 |
| Abdel-Hamid, AES; Abdel-Rahman, M; Galhom, RA; Mohammed Ali, MH; Nasr El-Din, WA | 1 |
| Marathe, PA; Nagarajan, VB | 1 |
| Benya-Aphikul, H; Rodsiri, R; Tansawat, R; Tantisira, MH; Teerapattarakan, N; Wanakhachornkrai, O | 1 |
| Chen, J; Chen, Y; Ge, R; Han, J; Hou, Y; Wang, H; Xu, J | 1 |
| He, D; Lei, L; Liu, M; Lou, D; Lu, S; Shi, Y; Song, Y; Wang, Z; Wu, S | 1 |
| Chen, C; Chen, F; Chen, J; Chen, Y; Du, R; Ge, R; Hou, Y; Wang, H; Yang, J | 1 |
| Elmazoglu, Z; Karasu, C; Sonmez, C; Yar Saglam, AS | 1 |
| Chen, S; Ding, F; He, Q; Lu, J; Shen, M; Shi, Y; Zhang, Q; Zhang, Y | 1 |
| Capps, J; Virga, DM; Vohra, BPS | 1 |
| da Silva Ribeiro, CY; de Aguiar Montenegro, N; de Andrade, RR; Del Bel Guimarães, E; Domingues, ACM; Ferreira, GG; Horst, CH; Schlemmer, F; Titze-de-Almeida, R; Titze-de-Almeida, SS | 1 |
| Fernández-Valverde, F; Granados-Rojas, L; Jiménez-Anguiano, A; Juárez-Zepeda, TE; Luis-Garcia, ER; Orozco-Ibarra, M; Orozco-Suárez, SA; Pedraza-Chaverri, J; Serrano-García, N | 1 |
| Ahmed, E; Alshareef, DM; El-Kherbetawy, MK; ElSayed, MH; Elsherbiny, NM; Mehanna, ET; Moustafa, YM; Zaitone, SA | 1 |
| Fang, Q; Homberg, JR; Li, W; Liao, P; Liu, C; Luan, Y; Meng, X; Shan, L; Shen, J; Swaab, DF; Wang, J; Zhou, P | 1 |
| Essa, MM; Guillemin, GJ; Karthik, R; Manigandan, V; Manivasagam, T; Nataraj, J; Saravanan, R; Thenmozhi, AJ | 1 |
| Hammock, BD; Hwang, SH; Krishnamurthy, PT; Lakkappa, N; M D, P | 1 |
| Fu, F; Han, B; Qi, GJ; Wang, L; Wang, T; Wang, Z; Zhang, L | 1 |
| Bhurtel, S; Choi, DY; Katila, N; Neupane, S; Srivastav, S | 1 |
| Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF | 1 |
| Avcı, B; Balcı, H; Bilge, SS; Bozkurt, A; Günaydın, C; Önger, ME | 1 |
| Bhandari, R; Kanwar, N; Kuhad, A; Sinha, VR | 1 |
| Chen, S; Liu, Y; Mo, M; Song, C; Sun, C; Wang, X; Wang, Y; Yu, W | 1 |
| Abah, VO; Adebambo, OI; Aladelokun, OB; Awogbindin, IO; Ezekiel, IO; Farombi, EO; Farombi, TH; Izomoh, ER; Oladele, JO | 1 |
| Chen, S; Liu, Y; Mo, M; Song, C; Sun, C; Wang, X; Wang, Y | 1 |
| Abdelhamid, AM; Ibrahim, SM; Zaafan, MA | 1 |
| Karuppagounder, SS; Madathil, SK; Mohanakumar, KP | 1 |
| Gai, WP; Meedeniya, A; Pountney, DL; Rcom-H'cheo-Gauthier, A; Sharry, S; Weetman, J; Wong, MB | 1 |
| Huang, J; Jia, M; Lin, Z; Liu, L; Mohamed, AA; Wang, T; Xiong, J; Xiong, N; Yang, H; Zhang, X; Zhang, Z | 1 |
| Lu, J; Shi, JP; Shi, JQ; Tian, YY; Wu, L; Xie, W; Zhang, YD | 1 |
| Elangovan, N; Jayaraj, RL; Manivasagam, T; Tamilselvam, K | 1 |
| Gupta, SP; Mishra, SK; Singh, MP; Singhal, NK; Tiwari, MN; Yadav, S | 1 |
| Castro, MA; Da Cunha, C; Delattre, AM; Dombrowski, PA; Dos Santos, AC; Ferraz, AC; Jose, EA; Lima, MM | 1 |
| Dagda, RK; Das Banerjee, T; Janda, E | 1 |
| Nehru, B; Thakur, P | 1 |
| Li, WW; Lu, CZ; Zhu, M | 1 |
| Chen, N; He, W; Hu, J; Li, B; Yuan, Y; Zhang, W | 1 |
| Baggio, CH; Barbiero, JK; Bassani, TB; Gradowski, RW; Maria-Ferreira, D; Santiago, RM; Vital, MA; Zaminelli, T | 1 |
| Ding, F; Jiang, C; Ke, K; Qin, J; Zhang, J; Zhang, Q | 1 |
| Asanuma, M; Miyazaki, I; Miyoshi, K; Murakami, S; Sogawa, N | 1 |
| Fridell, YW; Hwang, RD; Kannan, K; Khan, M; LaBreck, CJ; Lee, D; Wang, X; Wiemerslage, L; Zhu, X | 1 |
| Chang, CJ; Chu, CT; Dickinson, BC; Greenamyre, JT; Hu, X; Mastroberardino, PG; McCoy, J; Sanders, LH; Van Houten, B | 1 |
| Abd El-Rehim, HA; El-Ghazaly, MA; Rashed, ER | 1 |
| Guo, K; Huang, J; Lin, Z; Liu, L; Liu, S; Wang, D; Wang, L; Wang, T; Wu, P; Xiong, J; Xiong, N; Yang, J; Zhang, G; Zhang, X; Zhang, Z | 1 |
| Kabiraj, P; Marin, JE; Narayan, M; Varela-Ramirez, A; Zubia, E | 1 |
| Chang, YM; Chen, CH; Chen, CL; Chen, YJ; Chiu, CC; Huang, YC; Lai, SC; Lu, CS; Mochly-Rosen, D; Wang, HL; Wu-Chou, YH; Yeh, TH | 1 |
| Andreatini, R; Barbiero, JK; Bassani, TB; Boschen, SL; da Cunha, C; Gradowski, RW; Lima, MM; Santiago, RM; Vital, MA; Zaminelli, T | 1 |
| Gu, JH; Guan, JJ; Hou, YS; Qin, ZH; Wu, F; Xu, HD; Zhen, XC | 1 |
| Alam, M; John, N; Krauss, JK; Schwabe, K; von Wrangel, C | 1 |
| Ateş, U; Çavuşoğlu, T; Çınar, BP; Erbaş, O; Solmaz, V | 1 |
| Bhattacharya, P; Bhattacharyya, A; Chakrabarti, N; Dutta, SS; Mitra, S; Ray, S; Sinha, P | 1 |
| Hassanzadeh, K; Izadpanah, E; Khosrobakhsh, F; Moloudi, MR; Rahimmi, A | 1 |
| Bayır, H; Domingues, MR; Greenamyre, JT; Kagan, VE; Kapralova, VI; Maciel, E; McCoy, J; Polimova, AM; Sanders, LH; Tyurin, VA; Tyurina, YY; Vikulina, AS; Winnica, DE | 1 |
| Lavalley, N; McFerrin, M; Slone, SR; Wang, B; Yacoubian, TA | 1 |
| Bazan, NG; Calandria, JM; Sharp, MW | 1 |
| Bai, Q; Burton, EA; Cannon, JR; El Ayadi, A; Greenamyre, JT; Hastings, TG; Horowitz, MP; Shah, V; Tapias, V; Zharikov, AD | 1 |
| Bai, J; Guan, Q; Liu, Z; Wang, M; Wang, X; Yan, Z; Yang, L; Zhang, Y | 1 |
| Du, X; Jiang, H; Xie, J; Xu, H; Zhang, Z | 1 |
| Gao, G; Liu, J; Wang, H; Wang, X; Wu, X; Yang, H | 1 |
| Chen, NH; Chu, SF; Li, J; Liu, Y; Song, LK; Sun, JD; Yuan, YH | 1 |
| Araujo, SM; Bortolotto, VC; de Paula, MT; Jesse, CR; Meichtry, L; Poetini, MR; Prigol, M; Zarzecki, MS | 1 |
| Bakshi, R; Gu, L; Liu, L; Wang, ST; Xia, N; Yang, H; Yang, HM; Zhang, H; Zhang, Q | 1 |
| Jiang, H; Shen, X; Xu, H; Yu, J | 1 |
| Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandizzi, C; Colucci, R; Fornai, M; Pellegrini, C | 1 |
| Abul Khair, SB; Azimullah, S; Haque, ME; Javed, H; Ojha, S | 3 |
| Han, C; Hou, L; Huang, J; Li, J; Lin, Z; Liu, L; Wang, T; Xiong, N; Xu, X; Zhang, G | 1 |
| Chakrapani, LN; Kaliappan, K; Krishnan, TR; Narasimhan, KK; Paul, L; Periandavan, K; Radhakrishnan, R; Ravi, DB; Sathyamoorthy, YK; Singh, A; Srinivasan, A; Velusamy, P | 1 |
| Rajini, PS; Rao, SV; Yenisetti, SC | 1 |
| Carriere, CH; Kang, NH; Niles, LP | 1 |
| Dikalova, YV; Khudoerkov, RM; Sheloukhova, LI; Voronkov, DN | 1 |
| Dhanalakshmi, C; Essa, MM; Guillemin, GJ; Janakiraman, U; Justin Thenmozhi, A; Kalandar, A; Khan, MA; Manivasagam, T | 1 |
| Deng, YN; Qu, QM; Su, H; Zhang, JY; Zhang, M | 1 |
| El-Horany, HE; El-Latif, RN; ElBatsh, MM; Emam, MN | 1 |
| Abdelkader, NF; El-Sayeh, BM; Kandil, EA; Saleh, S | 1 |
| Brenton, J; Cordeiro, MF; Davis, BM; De Groef, L; Guo, L; Malaguarnera, G; Nizari, S; Normando, EM; Pahlitzsch, M; Ravindran, N; Somavarapu, S; Turner, LA | 1 |
| Das, M; Kundu, P; Sahoo, SK; Tripathy, K | 1 |
| Barcia, E; Boeva, L; Fernandez-Carballido, A; Garcia-García, L; Negro, S; Slowing, K | 1 |
| Cai, DF; Cai, M; Li, WW; Li, XT; Wu, T; Xiang, J; Yu, ZH; Zhang, JS; Zhang, W; Zhang, ZN | 1 |
| Fu, F; Han, B; Li, C; Li, J; Lv, Y; Wang, L; Wang, S; Wang, T; Wang, Z | 1 |
| Arambakkam Janardhanam, V; Gopi, M | 1 |
| Ameen, AM; Barakat, BM; Elkazaz, AY; Mohammad, HMF | 1 |
| Akaike, A; Inden, M; Inoue, H; Izumi, Y; Kihara, T; Kitamura, Y; Sawada, H; Shimohama, S; Takahashi, R; Takata, K; Takeuchi, H; Taniguchi, T; Uemura, K; Yamakawa, K; Yamamoto, N; Yanagida, T | 1 |
| Abdin, AA; Hamouda, HE | 1 |
| Banik, NL; Butler, JT; Ray, SK; Samantaray, S | 1 |
| Abou-Sleiman, P; Bandmann, O; Cookson, MR; Klaffke, S; Koopman, WJ; Mortiboys, H; Olpin, S; Smeitink, JA; Thomas, KJ; Willems, PH; Wood, NW | 1 |
| Cannon, JR; Drolet, RE; Greenamyre, JT; Honick, AS; Na, HM; Tapias, V | 1 |
| Alam, M; Danysz, W; Dekundy, A; Schmidt, WJ | 1 |
| Ariga, H; Inden, M; Kitamura, Y; Shibaike, T; Taira, T; Takata, K; Tamaki, A; Taniguchi, T; Yamamoto, A; Yanagida, T; Yasui, H | 1 |
| Cannon, JR; Greenamyre, JT; Tapias, V | 1 |
| Feng, L; Huang, R; Jiang, C; Ke, W; Liu, Y; Pei, Y; Wu, D | 1 |
| Corona, JC; Díaz-Nido, J; Gimenez-Cassina, A; Lim, F | 1 |
| Behl, C; Hajieva, P; Kern, A; Mocko, JB; Moosmann, B | 1 |
| Ayton, S; Culvenor, JG; Finkelstein, DI; George, S; Li, QX; Masters, CL; Mok, SS; Nurjono, M | 1 |
| Cao, X; Chen, C; Huang, J; Jia, M; Liang, Z; Lin, Z; Sun, S; Wang, T; Xiong, J; Xiong, N; Zhang, Z | 2 |
| Kuruvilla, KP; Nandhu, MS; Paul, J; Paulose, CS | 1 |
| Funk, RH; Pan-Montojo, FJ | 1 |
| Abe, M; Inden, M; Kitamura, Y; Takata, K; Tamaki, A; Taniguchi, T | 1 |
| Bhudhikanok, GS; Blair, A; Cambi, F; Chade, AR; Comyns, K; Fernandez, HH; Goldman, SM; Hoppin, JA; Kamel, F; Kasten, M; Korell, M; Langston, JW; Marras, C; Meng, C; Priestley, B; Richards, MB; Ross, GW; Sandler, DP; Tanner, CM; Umbach, DM | 1 |
| Dowd, E; Mulcahy, P; Paucard, A; Rea, K; Walsh, S | 1 |
| Kumar, P; Kuruvilla, KP; Mathew, J; Paul, J; Paulose, CS | 1 |
| Cao, X; Chen, C; Hou, L; Huang, J; Jia, M; Liang, Z; Lin, Z; Sun, S; Wang, T; Xiong, N; Yang, H; Zhang, Y; Zhang, Z; Zhao, Y | 1 |
| Chen, C; Feng, Y; Huang, J; Khare, G; Lin, Z; Qiao, X; Reesaul, H; Sun, S; Wang, T; Xiong, J; Xiong, N; Zhang, Y; Zhang, Z; Zhao, Y | 1 |
| Barcia, E; Fernández, M; Fernández-Carballido, A; Negro, S; Slowing, K | 1 |
| Johnson, SW; Wu, YN | 1 |
| Ariza, D; Barbiero, JK; Bortolanza, M; Da Cunha, C; Dombrowski, PA; Lima, MM; Moreira, CG; Sabioni, P; Vital, MA | 1 |
| Cuenca, N; Esquiva, G; Esteve-Rudd, J; Lax, P; Madrid, JA; Otalora, BB | 1 |
| Ambasta, RK; Anand, K; Chaterjee, P; Kumar, P; Sonia Angeline, M | 1 |
| Barreto, GE; Cabezas, R; El-Bachá, RS; González, J | 1 |
| Cabeza-Arvelaiz, Y; Schiestl, RH | 1 |
| Ariga, H; Ashihara, E; Honmou, O; Inden, M; Kitamura, Y; Nishimura, K; Shimohama, S; Takata, K; Yoshimoto, K | 1 |
| Bashkatova, VG; Sudakov, SK | 1 |
| Cannon, JR; Dail, MK; Geghman, KD; Greenamyre, JT; Li, C; Sew, T; Tapias, V | 1 |
| Haobam, R; Karuppagounder, SS; Madathil, KS; Mohanakumar, KP; Rajamma, U; Varghese, M | 1 |
| Haobam, R; Karuppagounder, SS; Madathil, SK; Mohanakumar, KP; Pandey, M; Rajamma, U | 1 |
| Betarbet, R; Greenamyre, JT; Kim, JH; Sherer, TB | 1 |
| Orth, M; Tabrizi, SJ | 1 |
| Carrard, G; Friguet, B; Hirsch, EC; Höglinger, GU; Lombès, A; Medja, F; Michel, PP; Ruberg, M | 1 |
| Betarbet, R; Greenamyre, JT; Sherer, TB | 1 |
| Betarbet, R; Greenamyre, JT; Kim, JH; Matsuno-Yagi, A; Miller, GW; Richardson, JR; Seo, BB; Sherer, TB; Testa, CM; Yagi, T | 1 |
| Alam, M; Mayerhofer, A; Schmidt, WJ | 1 |
| Alam, M; Schmidt, WJ | 1 |
| Birman, S; Coulom, H | 1 |
| Fujikawa, T; Hayashi, I; Kanada, N; Nakashima, K; Ogata, M; Shimada, A; Suzuki, I | 1 |
| Ding, JH; Hu, G; Liu, SY; Liu, X; Long, Y; Sun, YH; Wang, F; Wang, H; Wu, J; Yang, Y; Yao, HH | 2 |
| Ahmadi, F; Fariss, MW; Grammatopoulos, TN; Jones, SM; Weyhenmeyer, JA; Zawada, WM | 1 |
| Baranyi, M; Kittel, A; Milusheva, E; Sperlágh, B; Vizi, ES | 1 |
| Mohanakumar, KP; Saravanan, KS; Sindhu, KM | 2 |
| Bence, NF; Betarbet, R; Canet-Aviles, RM; Cookson, MR; Greenamyre, JT; Kim, JH; Klinefelter, G; Kopito, R; Lund, S; Mastroberardino, PG; McLendon, C; Na, HM; Seo, BB; Sherer, TB; Taylor, G; Yagi, A; Yagi, T | 1 |
| Mohanakumar, KP; Saravanan, KS; Senthilkumar, KS; Sindhu, KM | 1 |
| Feng, J; Jiang, Q; Yan, Z | 1 |
| Biswas, SC; Greene, LA; Jackson-Lewis, V; Malagelada, C; Ryu, EJ | 1 |
| Hansen, JM; Jones, DP; Miller, GW; Ramachandiran, S; Richardson, JR | 1 |
| Hamann, M; Richter, A; Richter, F | 1 |
| Ariga, H; Inden, M; Kaneko, M; Kitamura, Y; Kobayashi, Y; Okuma, Y; Shimohama, S; Taira, T; Takata, K; Takeuchi, H; Taniguchi, T; Yanagida, T; Yoshimoto, K | 1 |
| Dingledine, R; Greenamyre, JT; Greene, JG | 1 |
| Greenamyre, JT; Marella, M; Matsuno-Yagi, A; Nakamaru-Ogiso, E; Seo, BB; Yagi, T | 1 |
| Ching, CH; Chuang, JI; Huang, JY; Lin, CH | 1 |
| Khanna, P; Nehru, B; Sharma, SK; Verma, R | 1 |
| James-Kracke, M; Miller, RL; Sun, AY; Sun, GY | 1 |
| Lotharius, J; O'Malley, KL | 1 |
| Helmuth, L | 1 |
10 review(s) available for rotenone and Parkinsonian Disorders
| Article | Year |
|---|---|
Use of invertebrates to model chemically induced parkinsonism-symptoms.
Topics: Animals; Disease Models, Animal; Humans; Invertebrates; Parkinson Disease; Parkinsonian Disorders; Rotenone | 2023 |
Chemical and Genetic Zebrafish Models to Define Mechanisms of and Treatments for Dopaminergic Neurodegeneration.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Gene Knockdown Techniques; Neurotoxicity Syndromes; Oxidopamine; Paraquat; Parkinson Disease; Parkinsonian Disorders; Protein Serine-Threonine Kinases; Rotenone; Zebrafish; Zebrafish Proteins | 2020 |
An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.
Topics: Adverse Outcome Pathways; Animals; Electron Transport Complex I; Humans; Mitochondria; Parkinsonian Disorders; Pesticides; Rotenone | 2018 |
Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?
Topics: Animals; Humans; Methamphetamine; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Parkinsonian Disorders; Reactive Nitrogen Species; Rotenone | 2014 |
How Parkinsonian toxins dysregulate the autophagy machinery.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Autophagy; Humans; Methamphetamine; Mitophagy; MPTP Poisoning; Neurotoxins; Oxidopamine; Paraquat; Parkinsonian Disorders; Rotenone | 2013 |
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
Topics: alpha-Synuclein; Animals; Cholecystokinin; Efferent Pathways; Enteric Nervous System; Gastric Emptying; Gastrointestinal Motility; Gastroparesis; Humans; Mice; Mice, Transgenic; Models, Neurological; Neuromuscular Junction; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Protein Aggregates; Rats; Rotenone; Translational Research, Biomedical; Vagus Nerve | 2015 |
Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone.
Topics: Agricultural Workers' Diseases; Animals; Apoptosis; Astrocytes; Brain; Chaperonins; Electron Transport; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; Lipid Peroxidation; Mitochondria; Mitochondrial Membranes; Nerve Tissue Proteins; Neurodegenerative Diseases; NF-kappa B; Oxidative Stress; Parkinsonian Disorders; Pesticides; Rotenone; Superoxide Dismutase; Transcription Factors | 2012 |
Models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; DNA Mutational Analysis; Dopamine Agents; Humans; Mice; Mice, Knockout; Mice, Transgenic; Models, Genetic; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Risk Factors; Rotenone; Substantia Nigra; Synucleins | 2003 |
The rotenone model of Parkinson's disease: genes, environment and mitochondria.
Topics: Environmental Exposure; Genetic Predisposition to Disease; Humans; Insecticides; Mitochondria; Parkinsonian Disorders; Rotenone | 2003 |
Oxidative and inflammatory pathways in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Herbicides; Humans; Inflammation; Lipopolysaccharides; Microglia; Mitogen-Activated Protein Kinases; NADPH Oxidases; Neurotoxins; Nitric Oxide Synthase; Oxidative Stress; Oxidopamine; Paraquat; Parkinson Disease; Parkinsonian Disorders; Protein Kinase C; Rotenone | 2009 |
191 other study(ies) available for rotenone and Parkinsonian Disorders
| Article | Year |
|---|---|
Rotenone-Induced Neurodegeneration Is Enabled by a p38-Parkin-ROS Signaling Feedback Loop.
Topics: Animals; Cell Line; Feedback, Physiological; Insecticides; Mice; p38 Mitogen-Activated Protein Kinases; Parkinsonian Disorders; Reactive Oxygen Species; Rotenone; Signal Transduction; Ubiquitin-Protein Ligases | 2021 |
Topics: Animals; Disease Models, Animal; Glutamates; Humans; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rotenone | 2022 |
Dihydroquercetin improves rotenone-induced Parkinsonism by regulating NF-κB-mediated inflammation pathway in rats.
Topics: Animals; Disease Models, Animal; Inflammation; Male; Neuroprotective Agents; NF-kappa B; Parkinsonian Disorders; Quercetin; Rats; Rats, Wistar; Rotenone | 2022 |
Neuroprotective effects of catechin and quercetin in experimental Parkinsonism through modulation of dopamine metabolism and expression of IL-1β, TNF-α, NF-κB, IκKB, and p53 genes in male Wistar rats.
Topics: Animals; Catechin; Dopamine; Genes, p53; Inflammation; Male; Neuroprotective Agents; NF-kappa B; Oxidative Stress; Parkinsonian Disorders; Quercetin; Rats; Rats, Wistar; Rotenone; Tumor Necrosis Factor-alpha | 2022 |
Non-Reproducibility of Oral Rotenone as a Model for Parkinson's Disease in Mice.
Topics: alpha-Synuclein; Animals; Body Weight; Chromatography, Liquid; Disease Models, Animal; Mice; Mice, Inbred C57BL; Parkinson Disease; Parkinsonian Disorders; Rotenone; Substantia Nigra; Tandem Mass Spectrometry | 2022 |
Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Basic Helix-Loop-Helix Transcription Factors; Brain-Derived Neurotrophic Factor; Calcium; Cyclic AMP Response Element-Binding Protein; Glycogen Synthase Kinase 3 beta; Mice; Neuronal Plasticity; Neuroprotective Agents; Parkinsonian Disorders; Rotenone | 2023 |
Protective effects of evening primrose oil on behavioral activities, nigral microglia and histopathological changes in a rat model of rotenone-induced parkinsonism.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Dopamine; Male; Microglia; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Rats; Rotenone | 2023 |
[Characteristics of behavioral reactions and the profile of brain isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism].
Topics: Animals; Brain; Carrier Proteins; Isatin; Mice; Neurotoxins; Parkinsonian Disorders; Rats; Rotenone | 2023 |
Novel trajectories of the NK1R antagonist aprepitant in rotenone-induced Parkinsonism-like symptoms in rats: Involvement of ERK5/KLF4/p62/Nrf2 signaling axis.
Topics: Animals; Antioxidants; Aprepitant; Kruppel-Like Factor 4; Mitogen-Activated Protein Kinase 7; Neuroprotective Agents; NF-E2-Related Factor 2; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Rats; Receptors, Neurokinin-1; Rotenone; Signal Transduction | 2023 |
Betanin improves motor function and alleviates experimental Parkinsonism via downregulation of TLR4/MyD88/NF-κB pathway: Molecular docking and biological investigations.
Topics: Animals; Betacyanins; Down-Regulation; Male; Malondialdehyde; Mice; Molecular Docking Simulation; Myeloid Differentiation Factor 88; NF-kappa B; Parkinson Disease; Parkinsonian Disorders; Rotenone; Toll-Like Receptor 4 | 2023 |
Enhancing the neuroprotective effect of squid outer skin astaxanthin against rotenone-induced neurotoxicity in in-vitro model for Parkinson's disease.
Topics: Animals; Antioxidants; Decapodiformes; Humans; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Rotenone | 2023 |
Quantitative changes of brain isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism.
Topics: Animals; Brain; Carrier Proteins; Humans; Isatin; Neurotoxins; Parkinsonian Disorders; Proteomics; Rats; Rotenone | 2023 |
Naringenin, a Functional Food Component, Improves Motor and Non-Motor Symptoms in Animal Model of Parkinsonism Induced by Rotenone.
Topics: Animals; Antioxidants; Disease Models, Animal; Functional Food; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rotenone | 2023 |
Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms.
Topics: Animals; Caspase 8; Dopamine; Ferroptosis; HSP90 Heat-Shock Proteins; Molecular Chaperones; Parkinson Disease; Parkinsonian Disorders; Rats; Rotenone | 2023 |
Neuroprotective effects of isatin and afobazole in rats with rotenone-induced Parkinsonism are accompanied by increased brain levels of Triton X-100 soluble alpha-synuclein.
Topics: alpha-Synuclein; Animals; Brain; Isatin; Neuroprotective Agents; Octoxynol; Parkinsonian Disorders; Proteomics; Rats; Rotenone | 2023 |
α-Arbutin Protects Against Parkinson's Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo.
Topics: Adenosine Triphosphate; Adenylate Kinase; Animals; Antioxidants; Apoptosis; Arbutin; Autophagy; Cell Line, Tumor; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Ericaceae; Female; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neuroblastoma; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Rotenone; Ubiquitin-Protein Ligases | 2020 |
Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression.
Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Caffeine; Drug Synergism; Edaravone; Lipid Peroxidation; Male; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Uncoupling Agents | 2019 |
Neuroprotective effects of mitoquinone and oleandrin on Parkinson's disease model in zebrafish.
Topics: Animals; Cardenolides; Disease Models, Animal; Female; Fish Proteins; Gene Expression; Locomotion; Male; Mitochondria; Neuroprotective Agents; Organophosphorus Compounds; Parkinson Disease; Parkinsonian Disorders; Rotenone; Synucleins; Ubiquinone; Zebrafish | 2020 |
Modulation of key enzymes linked to Parkinsonism and neurologic disorders by Antiaris africana in rotenone-toxified rats.
Topics: Acetylcholinesterase; Animals; Antiaris; Dopamine; Glutamate-Ammonia Ligase; Male; Mitochondria; Nervous System Diseases; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Peroxidase; Plant Extracts; Rats; Rats, Wistar; Rotenone; Sodium-Potassium-Exchanging ATPase; Ubiquinone | 2019 |
Protective Effect of (-)Epigallocatechin-3-gallate on Rotenone-Induced Parkinsonism-like Symptoms in Rats.
Topics: Animals; Apoptosis; Behavior, Animal; Catechin; Corpus Striatum; Disease Models, Animal; Encephalitis; Inflammation Mediators; Male; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar; Rotenone | 2020 |
Naringin Exhibits Neuroprotection Against Rotenone-Induced Neurotoxicity in Experimental Rodents.
Topics: Alkaloids; Animals; Dopamine; Drug Evaluation, Preclinical; Electron Transport Chain Complex Proteins; Exploratory Behavior; Flavanones; Gait; Hand Strength; Injections, Intraventricular; Locomotion; Male; Mitochondria; Neuroprotection; Neuroprotective Agents; Oxidative Stress; Oxygen Consumption; Parkinsonian Disorders; Rats; Rats, Wistar; Rotarod Performance Test; Rotenone; Stereotaxic Techniques; Substantia Nigra | 2020 |
Mechanistic evaluation of Ursolic acid against rotenone induced Parkinson's disease- emphasizing the role of mitochondrial biogenesis.
Topics: Animals; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Glutathione; Male; Mitochondria; Organelle Biogenesis; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Triterpenes; Ursolic Acid | 2020 |
Dopamine, a key factor of mitochondrial damage and neuronal toxicity on rotenone exposure and also parkinsonic motor dysfunction-Impact of asiaticoside with a probable vesicular involvement.
Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Cell Death; Corpus Striatum; Dopamine; Dopaminergic Neurons; Levodopa; Neuronal Outgrowth; Neuroprotective Agents; Parkinsonian Disorders; PC12 Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Rotenone; Triterpenes | 2020 |
Monascin exhibits neuroprotective effects in rotenone model of Parkinson's disease via antioxidation and anti-neuroinflammation.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Encephalitis; Heterocyclic Compounds, 3-Ring; Male; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotenone | 2020 |
Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model.
Topics: Animals; Apoptosis; Cells, Cultured; Dopaminergic Neurons; Glucagon-Like Peptide-1 Receptor; Hippocampus; Male; MAP Kinase Signaling System; Mitochondria; Neuroprotective Agents; Parkinsonian Disorders; Peptides; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Gastrointestinal Hormone; Rotenone | 2020 |
Comparative study between bone marrow mesenchymal stem cell and their conditioned medium in the treatment of rat model of Parkinsonism.
Topics: Animals; Bone Marrow Cells; Cells, Cultured; Culture Media, Conditioned; Disease Models, Animal; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Male; Mesencephalon; Mesenchymal Stem Cells; Nestin; Neuropil; Parkinsonian Disorders; Rats; Rotenone; Stem Cells; Substantia Nigra; Synucleins | 2021 |
Kolaviron protects against nigrostriatal degeneration and gut oxidative damage in a stereotaxic rotenone model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopaminergic Neurons; Flavonoids; Gastrointestinal Microbiome; Male; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Plant Extracts; Rats; Rotenone; Stereotaxic Techniques; Substantia Nigra | 2020 |
Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Neuroprotection; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Rotenone; Triterpenes; Ursolic Acid | 2020 |
The neuroprotective action of lenalidomide on rotenone model of Parkinson's Disease: Neurotrophic and supportive actions in the substantia nigra pars compacta.
Topics: Animals; Brain-Derived Neurotrophic Factor; Calcium-Binding Proteins; Caspase 9; Cell Survival; Dopamine; Dopaminergic Neurons; Lenalidomide; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Pars Compacta; Rats; Rotenone; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2020 |
Ameliorative effects of flavonoids and polyketides on the rotenone induced Drosophila model of Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Brain; Catalase; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Flavonoids; Gene Expression Regulation, Enzymologic; Lipid Peroxidation; Locomotion; Oxidative Stress; Parkinsonian Disorders; Polyketides; Rotenone; Superoxide Dismutase | 2020 |
Apelin-13 Protects Dopaminergic Neurons against Rotenone-Induced Neurotoxicity through the AMPK/mTOR/ULK-1 Mediated Autophagy Activation.
Topics: AMP-Activated Protein Kinases; Animals; Apelin Receptors; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line; Dopaminergic Neurons; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Small Interfering; Rotenone; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model.
Topics: Aminopyridines; Animals; Cognitive Dysfunction; Insecticides; Male; Mice; Mice, Inbred C57BL; Microglia; Minocycline; Parkinsonian Disorders; Pyrroles; Rotenone | 2021 |
Anti-inflammatory and neuroprotective effects of natural cordycepin in rotenone-induced PD models through inhibiting Drp1-mediated mitochondrial fission.
Topics: Animals; Anti-Inflammatory Agents; Deoxyadenosines; Dose-Response Relationship, Drug; Dynamins; Insecticides; Male; Mitochondrial Dynamics; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotenone | 2021 |
The Beneficial Effect of Rice Bran Extract Against Rotenone-Induced Experimental Parkinson's Disease in Rats.
Topics: Animals; Disease Models, Animal; Oryza; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Rats; Rotenone | 2021 |
Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinson's disease in rats: Possible role of endocannabinoid system modulation.
Topics: Acetaminophen; alpha-Synuclein; Animals; Apoptosis; Corpus Striatum; Dopamine; Endocannabinoids; Male; Mesencephalon; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rotenone | 2021 |
Does the Operation of Mitochondrial ATP-Dependent Potassium Channels Affect the Structural Component of Mitochondrial and Endothelial Dysfunctions in Experimental Parkinsonism?
Topics: Adenosine Triphosphate; Animals; Male; Mitochondria; Myocardium; Parkinsonian Disorders; Potassium Channels; Rats; Rats, Wistar; Rotenone; Uridine | 2021 |
Exposure to PM2.5 aggravates Parkinson's disease via inhibition of autophagy and mitophagy pathway.
Topics: Animals; Autophagy; Inhalation Exposure; Insecticides; Male; Mice; Mice, Inbred C57BL; Mitophagy; Parkinsonian Disorders; Particulate Matter; PC12 Cells; Rats; Rotenone; Signal Transduction | 2021 |
Nanoemulsion Improves the Neuroprotective Effects of Curcumin in an Experimental Model of Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Emulsions; Male; Mice; Nanoparticles; Neuroprotective Agents; Parkinsonian Disorders; Rotenone | 2021 |
VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration.
Topics: Animals; Dopaminergic Neurons; Insecticides; Male; Nerve Degeneration; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Rotenone; Vesicular Glutamate Transport Protein 2 | 2021 |
Parkinsonism-like Disease Induced by Rotenone in Rats: Treatment Role of Curcumin, Dopamine Agonist and Adenosine A
Topics: Adenosine; Aged; Animals; Curcumin; Disease Models, Animal; Dopamine Agonists; Humans; Inflammation Mediators; Mice; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Rats; Receptor, Adenosine A2A; Rotenone | 2022 |
Diffusion kurtosis imaging detects the time-dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease.
Topics: Administration, Oral; Animals; Diffusion Tensor Imaging; Disease Progression; Dopaminergic Neurons; Insecticides; Male; Maze Learning; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Rotenone; Time Factors | 2021 |
Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models.
Topics: Adenine; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Astrocytes; Autophagy; Behavior, Animal; Dihydroxyphenylalanine; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Male; Motor Activity; Nerve Degeneration; NF-E2-Related Factor 2; Oleanolic Acid; Parkinsonian Disorders; Phenotype; Rats, Sprague-Dawley; Repressor Proteins; Rotenone; Signal Transduction; Sirolimus | 2021 |
Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hippocampus; Humans; Inflammation; Lipopolysaccharides; Mice; Microglia; Neuroprotective Agents; Oligomycins; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Plant Preparations; Rats; Rotenone; Tissue Culture Techniques | 2017 |
Thymoquinone exerts neuroprotective effect in animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Basal Ganglia; Behavior, Animal; Benzoquinones; Cytoprotection; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dynamins; Male; Motor Activity; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Rotenone; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases | 2017 |
Daily chronomics of proteomic profile in aging and rotenone-induced Parkinson's disease model in male Wistar rat and its modulation by melatonin.
Topics: Age Factors; Aging; Animals; Biomarkers; Brain; Circadian Rhythm; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Male; Melatonin; Nerve Tissue Proteins; Parkinsonian Disorders; Pineal Gland; Proteomics; Rats, Wistar; Rotenone; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substantia Nigra; Suprachiasmatic Nucleus; Time Factors | 2017 |
Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain; Dopaminergic Neurons; Exenatide; Lipid Peroxidation; Male; Neuroprotective Agents; Parkinsonian Disorders; Peptides; Rats; Rats, Sprague-Dawley; Rotenone; Tumor Necrosis Factor-alpha; Venoms | 2017 |
Cyclin-dependent kinase 5-mediated phosphorylation of CHIP promotes the tAIF-dependent death pathway in rotenone-treated cortical neurons.
Topics: Animals; Apoptosis Inducing Factor; Cell Death; Cerebral Cortex; Cyclin-Dependent Kinase 5; Mice; Neurons; Parkinsonian Disorders; Phosphorylation; Rotenone; Ubiquitin-Protein Ligases; Uncoupling Agents | 2018 |
Mechanistic evaluation of neuroprotective effect of estradiol on rotenone and 6-OHDA induced Parkinson's disease.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Brain; Cells, Cultured; Estradiol; Flow Cytometry; Lipid Peroxidation; Male; Maze Learning; Mice; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Reactive Oxygen Species; Rotenone | 2017 |
Serum Response Factor Promotes Dopaminergic Neuron Survival via Activation of Beclin 1-Dependent Autophagy.
Topics: alpha-Synuclein; Animals; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cell Survival; Dopaminergic Neurons; Male; Parkinsonian Disorders; PC12 Cells; Random Allocation; Rats; Rats, Inbred Lew; Rotenone; Substantia Nigra; Transcription Factors; Tyrosine 3-Monooxygenase | 2018 |
Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson's disease.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Disease Models, Animal; Male; Mitochondria; Nanoparticles; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Resveratrol; Rotenone; Stilbenes | 2018 |
Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease.
Topics: Animals; Astrocytes; Gene Expression; Humans; Insecticides; Male; Parkinsonian Disorders; Protein Deglycase DJ-1; Rats; Rats, Inbred Lew; Rotenone | 2018 |
Effects of Aging in the Striatum and Substantia Nigra of a Parkinson's Disease Animal Model.
Topics: Aging; Animals; Corpus Striatum; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone; Substantia Nigra; Uncoupling Agents | 2018 |
Zinc and linoleic acid pre-treatment attenuates biochemical and histological changes in the midbrain of rats with rotenone-induced Parkinsonism.
Topics: Animals; Antioxidants; Disease Models, Animal; Female; Glutathione; Levodopa; Linoleic Acid; Lipid Peroxidation; Parkinsonian Disorders; Rats, Wistar; Rotenone; Zinc | 2018 |
Myricetin attenuates neurodegeneration and cognitive impairment in Parkinsonism.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Dopamine; Dopaminergic Neurons; Drosophila melanogaster; Drug Evaluation, Preclinical; Flavonoids; Lipid Peroxidation; Male; Memory; Parkinsonian Disorders; Phaeophyceae; Rotenone | 2018 |
Therapeutic efficacy of olfactory stem cells in rotenone induced Parkinsonism in adult male albino rats.
Topics: Aging; Animals; Cells, Cultured; Male; Mesencephalon; Motor Activity; Olfactory Bulb; Parkinsonian Disorders; Rats; Rotenone; Stem Cell Transplantation; Stem Cells; Treatment Outcome; Tyrosine 3-Monooxygenase | 2018 |
Effect of montelukast in experimental model of Parkinson's disease.
Topics: Acetates; Animals; Cyclopropanes; Inflammation Mediators; Leukotriene Antagonists; Male; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Quinolines; Rats; Rats, Wistar; Rotenone; Sulfides; Treatment Outcome | 2018 |
Neuroprotective effect of a standardized extract of Centella asiatica ECa233 in rotenone-induced parkinsonism rats.
Topics: Animals; Antioxidants; Antiparkinson Agents; Catalase; Centella; Corpus Striatum; Dopaminergic Neurons; Male; Malondialdehyde; Neuroprotective Agents; Parkinsonian Disorders; Plant Extracts; Rats, Wistar; Rotenone; Substantia Nigra; Superoxide Dismutase; Triterpenes; Tyrosine 3-Monooxygenase | 2018 |
Protective effect of roscovitine against rotenone-induced parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Cyclin-Dependent Kinases; E2F1 Transcription Factor; Mice, Inbred C57BL; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Purines; Random Allocation; Retinoblastoma Protein; Roscovitine; Rotenone | 2018 |
Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism.
Topics: Adenosine Triphosphate; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Green Fluorescent Proteins; Membrane Potential, Mitochondrial; Membrane Proteins; Microscopy, Electron, Transmission; Mitochondria; Mitochondrial Diseases; Mitochondrial Proteins; Movement; Mutation; Paraquat; Parkinsonian Disorders; Protein Serine-Threonine Kinases; Rotenone | 2018 |
P75 Involved in the Ubiquitination of α-synuclein in Rotenone-based Parkinson's Disease Models.
Topics: alpha-Synuclein; Animals; Apoptosis; Cell Line, Tumor; Dopaminergic Neurons; Gene Expression Regulation; Humans; Nuclear Proteins; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Sprague-Dawley; Receptor, Nerve Growth Factor; Rotenone; Transcription Factor RelA; Ubiquitin-Protein Ligases; Ubiquitination | 2018 |
Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson's disease and inflammatory pathways.
Topics: Animals; Cell Line; Dose-Response Relationship, Drug; Hormesis; Inflammation; L-Lactate Dehydrogenase; Luteolin; Mice; Microglia; Oxidation-Reduction; Oxidative Stress; Parkinsonian Disorders; Rotenone | 2020 |
Mitochondrial regulation by pyrroloquinoline quinone prevents rotenone-induced neurotoxicity in Parkinson's disease models.
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Insecticides; Mitochondria; Parkinsonian Disorders; PQQ Cofactor; Rats; Rats, Sprague-Dawley; Rotenone | 2018 |
Enteric Neurodegeneration is Mediated Through Independent Neuritic and Somal Mechanisms in Rotenone and MPP+ Toxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; Enteric Nervous System; Female; Insecticides; Mice; MPTP Poisoning; Nerve Degeneration; Neurites; Parkinson Disease, Secondary; Parkinsonian Disorders; Pregnancy; Rotenone | 2018 |
Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Male; MicroRNAs; Neostriatum; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Rats, Wistar; Rotenone; Substantia Nigra | 2018 |
Docosahexaenoic acid protection in a rotenone induced Parkinson's model: Prevention of tubulin and synaptophysin loss, but no association with mitochondrial function.
Topics: Animals; Docosahexaenoic Acids; Male; Mitochondria; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone; Synaptophysin; Tubulin; Uncoupling Agents | 2018 |
Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: Relevance to Parkinson's disease therapy.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Apoptosis; Behavior, Animal; Caffeic Acids; CD11b Antigen; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Inflammation Mediators; Locomotion; Male; Mice; Motor Activity; Neuroprotective Agents; NF-kappa B; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2019 |
Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Brain; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Histamine; Indoles; Inflammation; Male; Microglia; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Histamine H4; Rotenone | 2019 |
Low Molecular Weight Sulfated Chitosan: Neuroprotective Effect on Rotenone-Induced In Vitro Parkinson's Disease.
Topics: Antiparkinson Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Chitosan; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Reactive Oxygen Species; Rotenone | 2019 |
Soluble epoxide hydrolase inhibitor, APAU, protects dopaminergic neurons against rotenone induced neurotoxicity: Implications for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Line; Cell Survival; Crystallography, X-Ray; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drosophila melanogaster; Epoxide Hydrolases; Humans; Insecticides; Male; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rotenone | 2019 |
Hydroxysafflor yellow A promotes α-synuclein clearance via regulating autophagy in rotenone-induced Parkinson's disease mice.
Topics: alpha-Synuclein; Animals; Autophagy; Brain; Chalcone; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinsonian Disorders; Quinones; Rotenone; Uncoupling Agents | 2018 |
Mechanistic comparison between MPTP and rotenone neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Brain; Dopamine; Male; Mice, Inbred C57BL; MPTP Poisoning; Neurons; Parkinsonian Disorders; Rotenone | 2019 |
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate | 2019 |
Effects of agomelatine in rotenone-induced Parkinson's disease in rats.
Topics: Acetamides; Animals; Apomorphine; Apoptosis; Brain; Cell Count; Corpus Striatum; Hypokinesia; Male; Neurons; Oxidation-Reduction; Parkinsonian Disorders; Proteins; Rats; Rotarod Performance Test; Rotation; Rotenone | 2019 |
Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain; Delayed-Action Preparations; Drug Liberation; Glutathione; Hydrogen-Ion Concentration; Indans; Injections, Subcutaneous; Lipid Peroxidation; Locomotion; Male; Microspheres; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinsonian Disorders; Polyesters; Rats, Sprague-Dawley; Rotenone; Superoxide Dismutase | 2019 |
Activation of the immunoproteasome protects SH-SY5Y cells from the toxicity of rotenone.
Topics: alpha-Synuclein; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP Binding Cassette Transporter, Subfamily B, Member 3; Cell Line, Tumor; Cysteine Endopeptidases; Gene Expression Regulation; Histocompatibility Antigens Class I; Humans; Neurons; Oxidative Stress; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Rotenone; Signal Transduction; Tyrosine 3-Monooxygenase | 2019 |
Neuroprotective role of kolaviron in striatal redo-inflammation associated with rotenone model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Apoptosis; Behavior, Animal; Corpus Striatum; Cytokines; Disease Models, Animal; Exploratory Behavior; Flavonoids; Inflammation Mediators; Locomotion; Male; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Reactive Oxygen Species; Rotenone; Tyrosine 3-Monooxygenase | 2019 |
Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson's Disease Rat Model.
Topics: Animals; Male; Minocycline; Nitric Oxide; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone; Substantia Nigra; Up-Regulation | 2019 |
The Protective Effect of Korean Red Ginseng Against Rotenone-Induced Parkinson's Disease in Rat Model: Modulation of Nuclear Factor-κβ and Caspase-3.
Topics: Animals; Apoptosis; Behavior, Animal; Caspase 3; Dopamine; Glutathione; Male; Neuroprotective Agents; NF-kappa B; Oxidative Stress; Panax; Parkinsonian Disorders; Plant Extracts; Random Allocation; Rats, Wistar; Republic of Korea; Rotenone | 2019 |
Sodium salicylate protects against rotenone-induced parkinsonism in rats.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Cyclooxygenase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Electron Transport Complex I; Glutathione; Hydroxyl Radical; Male; Neurons; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Sodium Salicylate; Substantia Nigra; Superoxide Dismutase; Uncoupling Agents | 2013 |
Increased SUMO-1 expression in the unilateral rotenone-lesioned mouse model of Parkinson's disease.
Topics: Aging; alpha-Synuclein; Animals; Brain; Disease Models, Animal; Humans; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Rotenone; SUMO-1 Protein; Up-Regulation | 2013 |
bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease.
Topics: Animals; Behavior, Animal; Cell Proliferation; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Motor Activity; Neurogenesis; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Time Factors | 2013 |
Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of candesartan cilexitil in the rotenone rat model of Parkinson's disease.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Endoplasmic Reticulum; Humans; Male; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Rotenone; Tetrazoles; Uncoupling Agents | 2013 |
Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Curcumin; Humans; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Pyrazoles; Rotenone | 2013 |
REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Cognition; Corpus Striatum; Disease Models, Animal; Injections, Intraventricular; Learning; Male; Memory; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone; Sleep Deprivation; Uncoupling Agents | 2013 |
Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson's disease in a rotenone-based model.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apoptosis; Carbenoxolone; DNA-Binding Proteins; Dopamine; Heat Shock Transcription Factors; Heat-Shock Proteins; Male; Mesencephalon; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Random Allocation; Rats; Rats, Sprague-Dawley; Rotenone; Transcription Factors; Tyrosine 3-Monooxygenase; Ubiquitin | 2014 |
Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; GTP Phosphohydrolases; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; MPTP Poisoning; Neuroprotective Agents; Parkinsonian Disorders; Rotenone; Uncoupling Agents | 2014 |
Flavin-containing monooxygenase, a new clue of pathological proteins in the rotenone model of parkinsonism.
Topics: Animals; Apoptosis; Caspase 3; Cells, Cultured; Dopaminergic Neurons; Enzyme Activation; Methimazole; Oxygenases; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Ubiquitin-Protein Ligases | 2014 |
Antidepressant and antioxidative effect of Ibuprofen in the rotenone model of Parkinson's disease.
Topics: Animals; Antidepressive Agents; Antioxidants; Brain; Catalase; Depression; Dose-Response Relationship, Drug; Glutathione; Ibuprofen; Male; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Random Allocation; Rats, Wistar; Rotenone; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2014 |
Involvement of ERK1/2 pathway in neuroprotective effects of pyrroloquinoline quinine against rotenone-induced SH-SY5Y cell injury.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; DNA, Mitochondrial; Electron Transport Complex I; Glutathione; Humans; Malondialdehyde; MAP Kinase Signaling System; Mitochondria; NADH Dehydrogenase; Neuroprotective Agents; Parkinsonian Disorders; PQQ Cofactor; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Rotenone; Superoxide Dismutase | 2014 |
Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice.
Topics: Animals; Astrocytes; Basal Ganglia; Cells, Cultured; Corpus Striatum; Dopaminergic Neurons; Male; Metallothionein; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Myenteric Plexus; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rotenone | 2014 |
The neuroprotective effect of human uncoupling protein 2 (hUCP2) requires cAMP-dependent protein kinase in a toxin model of Parkinson's disease.
Topics: Animals; Animals, Genetically Modified; Cell Survival; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cytoskeletal Proteins; Dopaminergic Neurons; Drosophila; Eye; Female; GTP-Binding Proteins; Humans; Intracellular Space; Ion Channels; Mitochondria; Mitochondrial Dynamics; Mitochondrial Proteins; Parkinsonian Disorders; Phenotype; Rotenone; Uncoupling Protein 2 | 2014 |
Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Biomarkers; Cells, Cultured; Cerebral Cortex; DNA Damage; DNA, Mitochondrial; Dopaminergic Neurons; Electron Transport Complex I; Humans; Hydrogen Peroxide; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Rats, Inbred Lew; Rotenone; Substantia Nigra | 2014 |
Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity.
Topics: Acrylic Resins; Animals; Catalepsy; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Male; Nanogels; Parkinsonian Disorders; Polyethylene Glycols; Polyethyleneimine; Povidone; Rats, Wistar; Rotenone; Spectroscopy, Fourier Transform Infrared; Treatment Outcome | 2015 |
Puerarin protects dopaminergic neurons in Parkinson's disease models.
Topics: Animals; Apoptosis; Brain; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Humans; Isoflavones; Male; Motor Activity; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotenone; Tyrosine 3-Monooxygenase; Ubiquitin; Vesicular Monoamine Transport Proteins | 2014 |
Ellagic acid mitigates SNO-PDI induced aggregation of Parkinsonian biomarkers.
Topics: alpha-Synuclein; Animals; Carrier Proteins; Cell Nucleolus; Ellagic Acid; Endoplasmic Reticulum Stress; Gene Expression Regulation; HSP70 Heat-Shock Proteins; Humans; Nerve Tissue Proteins; Nitric Oxide; Parkinsonian Disorders; PC12 Cells; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Disulfide-Isomerases; Rats; Reactive Nitrogen Species; Reactive Oxygen Species; Rotenone | 2014 |
Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism.
Topics: Aldehyde Dehydrogenase; Animals; Benzamides; Benzodioxoles; Cell Line; Disease Models, Animal; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Humans; Immunoblotting; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Microscopy, Confocal; MPTP Poisoning; Neurons; Parkinsonian Disorders; Rats; Reactive Oxygen Species; Rotenone; Uncoupling Agents | 2015 |
Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats.
Topics: Animals; Antidepressive Agents; Corpus Striatum; Dopamine; Male; Melatonin; Motor Activity; Neuroprotective Agents; Norepinephrine; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Serotonin; Tyrosine 3-Monooxygenase | 2014 |
Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Autophagy; Lysosomes; Male; Parkinsonian Disorders; Pars Compacta; PC12 Cells; Random Allocation; Rats; Rats, Inbred Lew; Rotenone; Trehalose; Tyrosine 3-Monooxygenase | 2015 |
The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.
Topics: Animals; Beta Rhythm; Disease Models, Animal; Male; Motor Activity; Motor Cortex; Neostriatum; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Rotenone; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2015 |
The neuroprotective effect of erythropoietin on experimental Parkinson model in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Dopaminergic Neurons; Erythropoietin; Male; Malondialdehyde; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2015 |
Gender-specific brain regional variation of neurons, endogenous estrogen, neuroinflammation and glial cells during rotenone-induced mouse model of Parkinson's disease.
Topics: Animals; Aromatase; Brain; Cell Nucleus; Cytosol; Dopa Decarboxylase; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Male; Mice; Neuroglia; Neuroimmunomodulation; Neurons; Parkinsonian Disorders; Random Allocation; Rotenone; Sex Characteristics; Tumor Necrosis Factor-alpha | 2015 |
N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins.
Topics: Acetylcysteine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drug Interactions; Dynamins; Male; Oxidative Stress; Parkinsonian Disorders; Protein Binding; Random Allocation; Rats; Rats, Wistar; Rotarod Performance Test; Rotenone; Substantia Nigra; Ubiquitin-Protein Ligases | 2015 |
LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease.
Topics: Animals; Arachidonic Acid; Biomarkers; Cardiolipins; Chromatography, High Pressure Liquid; Disease Models, Animal; Docosahexaenoic Acids; Linoleic Acid; Male; Mass Spectrometry; Mitochondria; Oxidation-Reduction; Parkinsonian Disorders; Rats, Inbred Lew; Rotenone; Substantia Nigra; Time Factors | 2015 |
Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.
Topics: 1-Methyl-4-phenylpyridinium; 14-3-3 Proteins; alpha-Synuclein; Animals; bcl-2-Associated X Protein; Casein Kinases; Cell Line, Tumor; Green Fluorescent Proteins; HEK293 Cells; Hippocampus; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Phosphorylation; Protein Serine-Threonine Kinases; Rotenone; Temporal Lobe | 2015 |
The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of Parkinson's Disease.
Topics: Animals; Cell Survival; Cells, Cultured; Docosahexaenoic Acids; Mesencephalon; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Tyrosine 3-Monooxygenase | 2015 |
shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Dopaminergic Neurons; Gene Knockdown Techniques; Male; Nerve Degeneration; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Rats, Transgenic; RNA, Messenger; RNA, Small Interfering; Rotenone; Substantia Nigra | 2015 |
Aging-related rotenone-induced neurochemical and behavioral deficits: role of SIRT2 and redox imbalance, and neuroprotection by AK-7.
Topics: Aging; Animals; Benzamides; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Neuroprotective Agents; Oxidation-Reduction; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Sirtuin 2; Substantia Nigra; Sulfonamides | 2015 |
Lesion of medullary catecholaminergic neurons is associated with cardiovascular dysfunction in rotenone-induced Parkinson's disease rats.
Topics: Animals; Blood Pressure; Dopamine; Dopamine beta-Hydroxylase; Dopaminergic Neurons; Electrocorticography; Epinephrine; Heart Rate; Male; Medulla Oblongata; Motor Activity; Norepinephrine; Parkinsonian Disorders; Pars Compacta; Rats; Rats, Wistar; Rotenone; Tyrosine 3-Monooxygenase | 2015 |
Protection effect of piperine and piperlonguminine from Piper longum L. alkaloids against rotenone-induced neuronal injury.
Topics: Alkaloids; Animals; Antiparkinson Agents; Apoptosis; Autophagy; Benzodioxoles; Brain; Cell Line; Dioxolanes; Drug Evaluation, Preclinical; Humans; Male; Mice; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Phytotherapy; Piper; Piperidines; Plant Extracts; Polyunsaturated Alkamides; Random Allocation; Rats, Wistar; Rotenone | 2016 |
Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apomorphine; Body Weight; Brain; Disease Progression; Dopamine; Dopamine Agonists; Enteric Nervous System; Environmental Exposure; Housing, Animal; Male; Mice, Inbred C57BL; Motor Activity; Muscle, Skeletal; Neurons; Olfactory Perception; Parkinsonian Disorders; Rotenone; Tyrosine 3-Monooxygenase | 2015 |
Effectiveness of γ-oryzanol in reducing neuromotor deficits, dopamine depletion and oxidative stress in a Drosophila melanogaster model of Parkinson's disease induced by rotenone.
Topics: Acetylcholinesterase; Animals; Antioxidants; Cell Survival; Dopamine; Drosophila melanogaster; Female; Insecticides; Male; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Phenylpropionates; Rotenone | 2015 |
Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model.
Topics: Animals; Blotting, Western; Cell Line; Comet Assay; Disease Models, Animal; DNA Damage; DNA Repair; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Rotenone; Uncoupling Agents | 2015 |
Ghrelin protects MES23.5 cells against rotenone via inhibiting mitochondrial dysfunction and apoptosis.
Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Ghrelin; Membrane Potential, Mitochondrial; Mitochondria; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rotenone | 2016 |
Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Brain; Calcium-Binding Proteins; Coumaric Acids; Cyclooxygenase 2; Cytokines; Cytoprotection; Disease Models, Animal; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Glutathione; Inflammation Mediators; Lipid Peroxidation; Male; Microfilament Proteins; Nerve Degeneration; Neuroprotective Agents; Nitric Oxide Synthase Type II; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Reactive Oxygen Species; Rotenone; Time Factors | 2015 |
Glycyrrhizic acid Attenuates Neuroinflammation and Oxidative Stress in Rotenone Model of Parkinson's Disease.
Topics: Animals; Calcium-Binding Proteins; Catalase; Corpus Striatum; Cyclooxygenase 2; Cytokines; Dopaminergic Neurons; Encephalitis; Glial Fibrillary Acidic Protein; Glutathione; Glycyrrhizic Acid; Inflammation Mediators; Lipid Peroxidation; Male; Microfilament Proteins; Nitric Oxide Synthase Type II; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone; Superoxide Dismutase | 2016 |
Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement.
Topics: Antiparkinson Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Drug Evaluation, Preclinical; Humans; Lithium Chloride; Matrix Metalloproteinases; Mitochondria; Neuroprotective Agents; Parkinsonian Disorders; Reactive Oxygen Species; Rotenone | 2015 |
Amelioration of apoptotic events in the skeletal muscle of intra-nigrally rotenone-infused Parkinsonian rats by Morinda citrifolia--up-regulation of Bcl-2 and blockage of cytochrome c release.
Topics: Animals; Antioxidants; Apoptosis; Aspartate Aminotransferases; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Creatine Kinase; Cytochromes c; Disease Models, Animal; L-Lactate Dehydrogenase; Male; Mitochondria; Morinda; Muscle, Skeletal; Oxidative Stress; Parkinsonian Disorders; Pars Compacta; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Rotenone; Up-Regulation | 2016 |
Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism.
Topics: Acetylcholinesterase; Animals; Antioxidants; Biomarkers; Carotenoids; Crocus; Disease Models, Animal; Dopamine; Drosophila melanogaster; Glutathione; Hydrogen Peroxide; Locomotion; Longevity; Mitochondria; Neuroprotective Agents; Nitric Oxide; Oxidative Stress; Paraquat; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Protein Carbonylation; Reactive Oxygen Species; Rotenone; Sulfhydryl Compounds | 2016 |
Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Immunohistochemistry; Male; Melatonin; Parkinsonian Disorders; Random Allocation; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Uncoupling Agents | 2016 |
Quantitative Evaluation of Changes in the Striatal Astrocyte Axons in Simulated Parkinsonism.
Topics: Animals; Astrocytes; Axons; Corpus Striatum; Glial Fibrillary Acidic Protein; Male; Oxidopamine; Paraquat; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone | 2016 |
Vanillin Attenuated Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and Apoptosis Against Rotenone Induced Rat Model of Parkinson's Disease.
Topics: Animals; Antioxidants; Apoptosis; Benzaldehydes; Dose-Response Relationship, Drug; Male; Maze Learning; Mental Disorders; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone | 2016 |
SIRT3 Acts as a Neuroprotective Agent in Rotenone-Induced Parkinson Cell Model.
Topics: Cell Line, Tumor; Cell Survival; Gene Knockdown Techniques; Humans; Neuroprotective Agents; Parkinsonian Disorders; Rotenone; Sirtuin 3 | 2016 |
Ameliorative Effect of Quercetin on Neurochemical and Behavioral Deficits in Rotenone Rat Model of Parkinson's Disease: Modulating Autophagy (Quercetin on Experimental Parkinson's Disease).
Topics: Animals; Antioxidants; Autophagy; Beclin-1; Body Weight; Catalepsy; Cognitive Dysfunction; Dopamine; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gene Expression Regulation; Injections, Intraperitoneal; Male; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Quercetin; Rats; Rotenone; Signal Transduction; Thioredoxin-Disulfide Reductase; Transcription Factor CHOP | 2016 |
Imipramine and amitriptyline ameliorate the rotenone model of Parkinson's disease in rats.
Topics: Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiparkinson Agents; Dopaminergic Neurons; Imipramine; Immunohistochemistry; Male; Microglia; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Rotarod Performance Test; Rotenone; Substantia Nigra | 2016 |
The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Topics: Animals; Antiparkinson Agents; Brain; Cell Survival; Cells, Cultured; Disease Progression; Drug Evaluation, Preclinical; Follow-Up Studies; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rats; Retina; Rosiglitazone; Rotenone; Superior Sagittal Sinus; Thiazolidinediones; Tomography, Optical Coherence | 2016 |
Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiparkinson Agents; Brain; Dopaminergic Neurons; Injections, Intraperitoneal; Lipid Peroxidation; Male; Molecular Structure; Neuroglia; Neuroimmunomodulation; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Rotenone; Sesquiterpenes | 2016 |
Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson's Disease.
Topics: Alkaloids; alpha-Synuclein; Animals; Antiparkinson Agents; Benzodioxoles; Blood-Brain Barrier; Capillary Permeability; Curcumin; Drug Delivery Systems; Drug Therapy, Combination; Liposomes; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Neuroprotective Agents; Parkinsonian Disorders; PC12 Cells; Piperidines; Polyunsaturated Alkamides; Protein Aggregation, Pathological; Random Allocation; Rats; Rotenone; Surface-Active Agents | 2016 |
Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism.
Topics: Animals; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Humans; Indoles; Insecticides; Lactic Acid; Male; Microspheres; Parkinsonian Disorders; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Rotenone; Treatment Outcome | 2017 |
Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study.
Topics: alpha-Synuclein; Animals; Body Weight; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Injections, Subcutaneous; Male; Mitochondria; Motor Activity; Neurons; Parkinsonian Disorders; Random Allocation; Rats, Wistar; Rotarod Performance Test; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
Hydroxysafflor Yellow A Improves Motor Dysfunction in the Rotenone-Induced Mice Model of Parkinson's Disease.
Topics: Animals; Chalcone; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Skills Disorders; Parkinsonian Disorders; Pigments, Biological; Quinones; Random Allocation; Rotarod Performance Test; Rotenone | 2017 |
Asiaticoside: Attenuation of rotenone induced oxidative burden in a rat model of hemiparkinsonism by maintaining the phosphoinositide-mediated synaptic integrity.
Topics: Animals; Behavior, Animal; Blotting, Western; Chromatography, High Pressure Liquid; Disease Models, Animal; Male; Maze Learning; Oxidative Stress; Parkinsonian Disorders; Phosphatidylinositols; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Rotarod Performance Test; Rotenone; Synapses; Triterpenes | 2017 |
Anti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats.
Topics: Animals; Anti-Inflammatory Agents; Locomotion; Male; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rotenone; Triterpenes | 2017 |
Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Topics: Animals; Behavior, Animal; Blotting, Western; Cholinergic Agents; Dopamine; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neurons; Nicotine; Parkinsonian Disorders; Receptors, Nicotinic; Rotenone; Substantia Nigra; Uncoupling Agents | 2009 |
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mitochondria; NAD; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Rats; Rotenone; Spectrophotometry; Ubiquinone; Ultrasonography; Vitamins | 2008 |
Extranigral neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calpain; Cell Line; Dipeptides; Humans; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rotenone; Spinal Cord; Substantia Nigra; Uncoupling Agents | 2008 |
Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.
Topics: Adenosine Triphosphate; Adult; Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Electron Transport Chain Complex Proteins; Energy Metabolism; Fibroblasts; Humans; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Mitochondrial Diseases; Mutation; Neuroprotective Agents; Parkinsonian Disorders; Rotenone; Ubiquitin-Protein Ligases; Uncoupling Agents | 2008 |
A highly reproducible rotenone model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Hypokinesia; Injections, Intraperitoneal; Male; Muscle Rigidity; Nerve Degeneration; Neurons; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Reproducibility of Results; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase; Ubiquitins; Uncoupling Agents | 2009 |
Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Basal Ganglia; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; Hypokinesia; Idazoxan; Male; Motor Activity; Muscle Rigidity; Neuroprotective Agents; Neurotoxicity Syndromes; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Adrenergic, alpha-2; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Rotenone; Serotonin; Substantia Nigra; Time Factors | 2009 |
Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Corpus Striatum; Cytochromes c; Dopamine; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Hydroxyl Radical; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Rotenone; Substantia Nigra; Uncoupling Agents | 2009 |
Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Topics: Animals; Body Weight; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Melatonin; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Random Allocation; Rats; Rats, Inbred Lew; Rotenone; Substantia Nigra; Survival Analysis; Tyrosine 3-Monooxygenase | 2010 |
Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model.
Topics: Animals; Chronic Disease; Disease Models, Animal; Gene Expression Regulation; Gene Transfer Techniques; Genes, Reporter; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Green Fluorescent Proteins; Lactoferrin; Male; Nanoparticles; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Treatment Outcome; Uncoupling Agents | 2010 |
Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalepsy; Cell Death; Dopamine; Genetic Therapy; Genetic Vectors; Herpesvirus 1, Human; Hexokinase; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Parkinsonian Disorders; Rotenone; Substantia Nigra; Treatment Outcome | 2010 |
Phenothiazines interfere with dopaminergic neurodegeneration in Caenorhabditis elegans models of Parkinson's disease.
Topics: Animals; Animals, Genetically Modified; Antipsychotic Agents; Caenorhabditis elegans; Disease Models, Animal; Dopamine; Humans; Insecticides; Models, Genetic; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Phenothiazines; Rotenone | 2010 |
α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Humans; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Oncogene Proteins; Parkinsonian Disorders; Peroxiredoxins; Protein Deglycase DJ-1; Protein Kinases; Rotenone; Ubiquitin-Protein Ligases; Uncoupling Agents; Up-Regulation | 2010 |
Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apomorphine; Brain; Carbocyanines; Cell Differentiation; Cell Movement; Corpus Striatum; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Intermediate Filament Proteins; Locomotion; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Neoplasm Proteins; Nerve Tissue Proteins; Nestin; Neurons; Parkinsonian Disorders; Pentylenetetrazole; Phosphopyruvate Hydratase; Rats; Rats, Sprague-Dawley; Rotation; Rotenone; Staining and Labeling; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase; Umbilical Cord; Ventral Tegmental Area | 2010 |
Dopamine D₁ and D₂ receptor subtypes functional regulation in corpus striatum of unilateral rotenone lesioned Parkinson's rat model: effect of serotonin, dopamine and norepinephrine.
Topics: Animals; Benzamides; Benzazepines; Catecholamines; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Functional Laterality; Male; Norepinephrine; Parkinsonian Disorders; Protein Binding; Radionuclide Imaging; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotarod Performance Test; Rotenone; Serotonin; Tritium | 2010 |
Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system.
Topics: Administration, Oral; alpha-Synuclein; Animals; Disease Models, Animal; Enteric Nervous System; Image Processing, Computer-Assisted; Intubation, Gastrointestinal; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Parkinsonian Disorders; Rotenone | 2010 |
Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice.
Topics: Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Male; Mice; Mice, Inbred C57BL; Neurons; Parkinsonian Disorders; Rotenone; Substantia Nigra; Uncoupling Agents | 2011 |
Rotenone, paraquat, and Parkinson's disease.
Topics: Aged; Case-Control Studies; Female; Herbicides; Humans; Insecticides; Iowa; Male; Middle Aged; Mitochondria; North Carolina; Occupational Exposure; Oxidative Stress; Paraquat; Parkinson Disease; Parkinsonian Disorders; Rotenone | 2011 |
Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Uncoupling Agents | 2011 |
Dopamine D₁ and D₂ receptor subtypes functional regulation in cerebral cortex of unilateral rotenone lesioned Parkinson's rat model: Effect of serotonin, dopamine and norepinephrine.
Topics: Animals; Cerebral Cortex; Dopamine; Functional Laterality; Male; Neurotransmitter Agents; Norepinephrine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Rotenone; Serotonin; Uncoupling Agents | 2011 |
Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Benzofurans; Cell Line; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Humans; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rotenone; Treatment Outcome | 2012 |
Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.
Topics: Animals; Antipyrine; bcl-2-Associated X Protein; Behavior, Animal; Dopamine; Edaravone; Free Radical Scavengers; Freezing Reaction, Cataleptic; Humans; Male; Neurons; Neuroprotective Agents; Neuropsychological Tests; Parkinsonian Disorders; Rats; Rats, Wistar; Reactive Oxygen Species; Rotenone; Uncoupling Agents; Vesicular Monoamine Transport Proteins | 2011 |
Glyceraldehyde-3-phosphate dehydrogenase: activity inhibition and protein overexpression in rotenone models for Parkinson's disease.
Topics: Animals; Blotting, Western; Gene Knockdown Techniques; Glyceraldehyde-3-Phosphate Dehydrogenases; Immunohistochemistry; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Rotenone; Uncoupling Agents | 2011 |
An effective novel delivery strategy of rasagiline for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Delayed-Action Preparations; Disease Models, Animal; Fluorodeoxyglucose F18; Indans; Injections, Intraperitoneal; Lactic Acid; Male; Microspheres; Multimodal Imaging; Parkinsonian Disorders; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Positron-Emission Tomography; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rotenone; Tomography, X-Ray Computed | 2011 |
Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons.
Topics: Animals; Dopamine; Male; Membrane Potentials; N-Methylaspartate; Neurons; Oxidation-Reduction; Parkinsonian Disorders; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rotenone; Substantia Nigra; Uncoupling Agents | 2011 |
Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopaminergic Neurons; Exploratory Behavior; Hydroxyindoleacetic Acid; Male; Microinjections; Motor Activity; Nerve Degeneration; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone; Serotonergic Neurons; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2012 |
Circadian dysfunction in a rotenone-induced parkinsonian rodent model.
Topics: Animals; Behavior, Animal; Biological Clocks; Body Temperature; Circadian Rhythm; Disease Models, Animal; Humans; Insecticides; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone | 2012 |
Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat.
Topics: Animals; Blotting, Western; Caspases; Fluorescent Antibody Technique; Heat-Shock Proteins; Male; Mental Disorders; Parkinsonian Disorders; Rats; Rats, Wistar; Rotenone; Transcriptome; Ubiquitin-Protein Ligases; Uncoupling Agents | 2012 |
Transcriptome analysis of a rotenone model of parkinsonism reveals complex I-tied and -untied toxicity mechanisms common to neurodegenerative diseases.
Topics: Action Potentials; Cell Line; Humans; Models, Biological; Neurodegenerative Diseases; Oligonucleotide Array Sequence Analysis; Parkinsonian Disorders; Rotenone; Transcriptome | 2012 |
Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice.
Topics: Animals; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred NOD; Mice, SCID; Nerve Growth Factors; Parkinsonian Disorders; Reverse Transcriptase Polymerase Chain Reaction; Rotenone; Uncoupling Agents | 2013 |
Role of metabotropic glutamate receptors in the mechanisms of experimental parkinsonism development.
Topics: Analysis of Variance; Animals; Catalepsy; Corpus Striatum; Male; Nitric Oxide; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotenone | 2012 |
Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.
Topics: alpha-Synuclein; Animals; Chromosomes, Artificial, Bacterial; Disease Models, Animal; Female; Humans; Male; Mitochondria; Parkinsonian Disorders; Pregnancy; Rats; Rats, Transgenic; Rotenone | 2013 |
Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats.
Topics: Animals; Antioxidants; Base Sequence; DNA Primers; Dopamine; Enzyme Inhibitors; Male; Nitric Oxide Synthase Type II; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Rotenone | 2013 |
Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats.
Topics: Animals; Antioxidants; Apoptosis; Disease Models, Animal; Electron Transport Complex I; Immunohistochemistry; In Situ Nick-End Labeling; Neuroprotective Agents; Parkinsonian Disorders; Quercetin; Rats; Rats, Sprague-Dawley; Rotenone; Uncoupling Agents; Up-Regulation | 2013 |
Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Infusion Pumps, Implantable; Injections, Subcutaneous; Insecticides; Male; Nerve Tissue Proteins; Neural Pathways; Neurodegenerative Diseases; Neurons; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Rotenone; Substantia Nigra; Synucleins; Time; Tyrosine 3-Monooxygenase | 2003 |
Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Animals; Cell Death; Cells, Cultured; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Electron Transport Complex I; Enzyme Inhibitors; Mesencephalon; Multienzyme Complexes; NADH, NADPH Oxidoreductases; Neurons; Neurotoxins; Oxidation-Reduction; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Rats; Rats, Wistar; Reactive Oxygen Species; Rotenone; Uncoupling Agents | 2003 |
Mechanism of toxicity in rotenone models of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Cell Death; Cell Line; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Electron Transport Complex I; Enzyme Inhibitors; Humans; In Vitro Techniques; Mesencephalon; Neuroblastoma; Neurons; Neuroprotective Agents; Olfactory Bulb; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Rotenone; Time | 2003 |
The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Chromatography, High Pressure Liquid; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reaction Time; Rotenone; Statistics, Nonparametric; Time Factors | 2004 |
L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dopamine; Drug Synergism; Electron Transport Complex I; Levodopa; Male; Motor Activity; Motor Skills; Muscle Rigidity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Uncoupling Agents | 2004 |
Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.
Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Count; Dopamine; Dopamine Agonists; Drosophila melanogaster; Electron Transport Complex I; Insecticides; Levodopa; Locomotion; Melatonin; Nerve Degeneration; Neurons; Oxidative Stress; Parkinsonian Disorders; Phenotype; Rotenone | 2004 |
Effect of sesamin in Acanthopanax senticosus HARMS on behavioral dysfunction in rotenone-induced parkinsonian rats.
Topics: Animals; Depressive Disorder; Dioxoles; Eleutherococcus; Lignans; Male; Parkinsonian Disorders; Plant Bark; Plant Extracts; Rats; Rats, Inbred Lew; Rotenone | 2005 |
Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Brain; Brain Chemistry; Catalepsy; Diazoxide; Disease Models, Animal; Dopamine; Down-Regulation; Drug Administration Schedule; Male; Nerve Tissue Proteins; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Propylamines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotenone; Uncoupling Agents | 2005 |
Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cell Death; Cells, Cultured; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Insecticides; Losartan; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Hydrogen Peroxide; Male; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Sulpiride; Tyrosine 3-Monooxygenase | 2005 |
Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Catalepsy; Decanoic Acids; Diazoxide; Disease Models, Animal; Dopamine; Hydroxy Acids; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels; Propylamines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotenone; Substantia Nigra | 2006 |
Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Topics: Adrenergic Agents; Amphetamine; Animals; Dopamine; Electron Transport Complex I; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Medial Forebrain Bundle; Microinjections; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Posture; Rats; Rotarod Performance Test; Rotenone; Stereotyped Behavior; Substantia Nigra | 2005 |
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Disease Models, Animal; Electron Transport Complex I; Energy Metabolism; Humans; Insecticides; Male; Mitochondria; Nerve Degeneration; Neurons; Oncogene Proteins; Oxidative Stress; Parkinsonian Disorders; Peroxiredoxins; Proteasome Endopeptidase Complex; Protein Deglycase DJ-1; Rats; Rats, Inbred Lew; Rotenone; Signal Transduction; Substantia Nigra; Ubiquitin | 2006 |
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Topics: Amphetamine; Animals; Catalase; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Electron Transport Complex I; Hydroxyl Radical; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2006 |
Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on dopaminergic neurons through a microtubule-dependent mechanism.
Topics: Animals; Cells, Cultured; Dopamine; Excitatory Amino Acid Agents; Female; Mesencephalon; Microtubules; Neurons; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Rotenone | 2006 |
RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Camptothecin; DNA-Binding Proteins; Gene Expression Regulation; Humans; Hydrogen Peroxide; Male; Melanins; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Growth Factor; Neurons; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; Rats; Repressor Proteins; Ribosomal Protein S6 Kinases, 70-kDa; RNA; RNA Interference; Rotenone; Signal Transduction; Substantia Nigra; TOR Serine-Threonine Kinases; Transcription Factors; Transcription, Genetic; Transfection; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Tunicamycin | 2006 |
Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Herbicides; Humans; Insecticides; JNK Mitogen-Activated Protein Kinases; Mitochondrial Proteins; Neurons; Oxidation-Reduction; Paraquat; Parkinsonian Disorders; Rotenone; Thioredoxins; Transfection | 2007 |
Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice.
Topics: Animals; Behavior, Animal; Brain; Follow-Up Studies; Gait; Lameness, Animal; Male; Mice; Mice, Inbred C57BL; Muscle Strength; Neurons; Parkinsonian Disorders; Rotenone; Survival; Tyrosine 3-Monooxygenase | 2007 |
Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model.
Topics: Animals; Catalase; Glutathione; Hydroxyl Radical; Male; Melatonin; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Submitochondrial Particles; Substantia Nigra; Superoxide Dismutase | 2007 |
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
Topics: alpha-Synuclein; Animals; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Endoplasmic Reticulum; Humans; Male; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Oxidative Stress; Parkinsonian Disorders; Phenylbutyrates; Rotenone; Substantia Nigra; Tauopathies | 2007 |
Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism.
Topics: Cell Line, Tumor; Gene Expression; Gene Expression Regulation; Humans; In Vitro Techniques; Insecticides; Oligonucleotide Array Sequence Analysis; Parkinsonian Disorders; Rotenone; Transcription, Genetic | 2008 |
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Dopamine; Male; NADH Dehydrogenase; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra | 2008 |
Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Down-Regulation; Melatonin; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Dopamine D2; Rotenone; Up-Regulation | 2008 |
Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Catalepsy; Disease Models, Animal; Dopamine; Drug Administration Schedule; Drug Interactions; Lipid Peroxidation; Male; Meclofenoxate; Motor Activity; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Treatment Outcome; Uncoupling Agents | 2008 |
The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Cells, Cultured; Dopamine; Kinetics; Mesencephalon; Mice; Neurons; Oxidation-Reduction; Parkinsonian Disorders; Reactive Oxygen Species; Rotenone | 2000 |
Neuroscience. Pesticide causes Parkinson's in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease Models, Animal; Dopamine; Electron Transport Complex I; Free Radicals; Humans; Insecticides; Lewy Bodies; Mitochondria; NADH, NADPH Oxidoreductases; Neurons; Parkinson Disease; Parkinsonian Disorders; Rats; Risk Factors; Rotenone; Uncoupling Agents | 2000 |